罕见病知识库 RareSeen

皮肤神经内分泌癌

Cutaneous neuroendocrine carcinoma

定义 英文原文(暂无中文)

A rare aggressive skin cancer characterized by a rapidly growing nodule with both epithelial and neuroendocrine features, driven in 80% of cases by the oncogenic Merkel cell polyomavirus (MCPyV).

别名

Merkel细胞癌

基本事实

遗传方式
不适用
发病年龄
成年期、老年期
患病率
1-9 / 1 000 000

临床表型 17

必现 100%1

  • 默克尔细胞皮肤癌 HP:0030447

常见 79–30%7

  • 细胞免疫缺陷 HP:0005374
  • 慢性非感染性淋巴结肿大 HP:0002730
  • 光感性皮肤 HP:0000992
  • 红斑病 HP:0025475
  • 红斑 HP:0025474
  • 皮肤局部异常 HP:0011356
  • 皮肤结节 HP:0200036

偶见 29–5%5

  • 基底细胞癌 HP:0002671
  • 类癌 HP:0100570
  • 淋巴细胞白血病 HP:0005526
  • 多发性骨髓瘤 HP:0006775
  • 皮肤鳞状上皮细胞癌 HP:0006739

罕见 <4–1%3

  • 脑FDG正电子发射断层扫描异常 HP:0012658
  • 脑肿瘤 HP:0030692
  • 外耳肿瘤 HP:0040095

排除 0%1

  • 疼痛 HP:0012531

近两年的全球研究 30L2

2024/08 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-07
    Inhibition of the ATR-CHK1 signaling pathway sensitizes MCPyV-positive Merkel cell carcinoma to gemcitabine
    BMC cancer · DOI · Europe PMC
  • 2026-05预印本
    A Case Report and Literature Review of Merkel Cell Carcinoma of the Face
    · DOI
  • 2026-05病例报告
    Merkel Cell Carcinoma With Divergent Differentiation-Or Something Else? A Triphasic Cutaneous Carcinoma With Lineage Plasticity
    Journal of cutaneous pathology · DOI · Europe PMC
  • 2026-05病例报告开放获取
    Expanding the dermoscopic spectrum of Merkel cell carcinoma: A case report
    JAAD case reports · DOI · Europe PMC
  • 2026-04预印本
    Merkel cell carcinoma in southern China: clinicopathologic and transcriptomic analysis with insights into an intraepidermal-predominant lesion
    · DOI
  • 2026-04综述病例报告
    Two cases of sweat gland carcinoma with neurosecretory differentiation: A report
    Indian journal of pathology & microbiology · DOI · Europe PMC
  • 2026-04综述病例报告开放获取
    Merkel Cell Carcinoma of the Thigh Presenting as a Hemorrhagic Mass: A Rare Case Report and Literature Review
    Current oncology (Toronto, Ont.) · DOI · Europe PMC
  • 2026-03开放获取
    A novel patient-specific solution for Merkel cell carcinoma in high-dose-rate brachytherapy
    Journal of contemporary brachytherapy · DOI · Europe PMC
  • 2026-02病例报告
    When Morphology Misleads: The Diagnostic Challenge of Large-Cell Variant Merkel Cell Carcinoma
    The American Journal of dermatopathology · DOI · Europe PMC
  • 2026-01
    Giant Palmar Merkel Cell Carcinoma With Prolonged Stability and Abrupt Progression
    International journal of dermatology · DOI · Europe PMC
  • 2026-01开放获取
    Merkel Cell Carcinoma Presenting as a Solitary Facial Nodule in a 59-Year-Old Woman
    The American Journal of dermatopathology · DOI · Europe PMC
  • 2026-01综述开放获取
    Imaging features of lacrimal gland disease
    Frontiers in ophthalmology · DOI · Europe PMC
  • 2025-12开放获取
    Optimizing surgical margins in the treatment of eyelid Merkel cell carcinoma: a tertiary center experience and literature review
    Frontiers in ophthalmology · DOI · Europe PMC
  • 2025-12综述开放获取
    RB1 inactivation in cutaneous carcinomas
    Histopathology · 被引 1 · DOI · Europe PMC
  • 2025-12开放获取
    Quantifying coding integrity and reliability of ICD-11 MMS for rare disease registration: a case study of the Chinese rare disease catalogue
    BMC medical informatics and decision making · DOI · Europe PMC
  • 2025-11开放获取
    Merkel cell carcinoma: Clinicopathological analysis of three patients and literature review
    Open life sciences · DOI · Europe PMC
  • 2025-10荟萃分析系统综述综述开放获取
    Dermatologic Features of Endocrine Tumor Syndromes-Systematic Review and Meta-Analysis
    International journal of dermatology · DOI · Europe PMC
  • 2025-10病例报告开放获取
    Merkel cell carcinoma of the parotid gland: a rare case report and literature review
    International journal of surgery case reports · DOI · Europe PMC
  • 2025-07开放获取
    Merkel cell carcinoma: long-term outcomes after radiotherapy treatment
    Clinical & translational oncology : official publication of the Federa · DOI · Europe PMC
  • 2025-06综述
    Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets
    Current oncology reports · 被引 1 · DOI · Europe PMC

境外已获批用于本病的药物 5L2

欧盟 2 项、美国 3 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

  • Bavencio欧盟2017-09-18
    avelumab
    官方记录
  • Zynyz欧盟2024-04-19
    retifanlimab
    官方记录
  • Bavencio美国2017-03-23
    avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1)
    官方记录
  • Keytruda美国2018-12-19
    pembrolizumab
    官方记录
  • Zynyz美国2023-03-22
    retifanlimab-dlwr
    官方记录
已获孤儿药资格、尚未获批的在研药物(7 项)

孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励,不代表这个药已被证明有效,也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • live-attenuated non-replicative Pseudomonas aeruginosa strain expressi欧盟2016-11-18
    Treatment of Merkel cell carcinoma
    官方记录
  • navtemadlin欧盟2022-01-14
    Treatment of Merkel cell carcinoma
    官方记录
  • activated natural killer[aNK])美国2017-03-15
    Treatment of Merkel cell carcinoma
    官方记录
  • navtemadlin美国2020-04-08
    Treatment of Merkel cell carcinoma
    官方记录
  • cavrotolimod美国2021-03-01
    Treatment of merkel cell carcinoma
    官方记录
  • bi-specific fragment crystallizable region (Fc) fusion protein contain美国2022-10-17
    Treatment of Merkel cell carcinoma
    官方记录
  • topotecan liposome injection美国2024-03-21
    Treatment of Merkel Cell Carcinoma
    官方记录

数据来自欧洲药品管理局(EMA)的药品与孤儿药资格公开导出表,以及美国 FDA 孤儿药资格数据库。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 2L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

当前没有检索到登记为可入组的试验。

其他状态的试验(2 项)
  • 进行中·不再招募NCT05544929
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
    I 期 · 干预性 · 2022/10/26Novartis Pharmaceuticals
    中国研究中心 2 个:Beijing、Guangzhou
  • 进行中·不再招募NCT05879822
    A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
    II 期 · 干预性 · 2023/10/30Incyte Corporation
    中国研究中心 1 个:Nanning

中国境外的在招试验 60L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

美国44澳大利亚10意大利6法国6德国5西班牙5日本3韩国3比利时2土耳其2爱尔兰2葡萄牙2加拿大2Uganda1另有 9 个国家/地区

共 25 项。

  • 尚未开始招募NCT07576725
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
    II 期 · 干预性 · 2026/09/01Fred Hutchinson Cancer Center
    Uganda
  • 尚未开始招募NCT07472322
    ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
    I 期、II 期 · 干预性 · 2026/08University of Wisconsin, Madison
    美国
  • 招募中NCT07749586
    A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
    I 期、II 期 · 干预性 · 2026/07/29Arvinas Inc.
    美国
  • 招募中NCT07600476
    A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
    I 期 · 干预性 · 2026/07/03Kupando GmbH
    德国
  • 招募中NCT07302347
    A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
    I 期、II 期 · 干预性 · 2026/06/23Merck Sharp & Dohme LLC
    日本
  • 招募中NCT07387198
    Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
    II 期 · 干预性 · 2026/05/29Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    德国
  • 招募中NCT07339176
    Intratumoral N17350 in Advanced Solid Tumors
    I 期、II 期 · 干预性 · 2026/05/25Onchilles Pharma Inc
    澳大利亚、美国
  • 招募中NCT07288073
    TIL Therapy in cSCC and MCC
    II 期 · 干预性 · 2026/02/10Karam Khaddour, MD, MS
    美国
  • 招募中NCT07215988
    Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
    观察性 · 2026/02/04Ohio State University Comprehensive Cancer Center
    美国
  • 招募中NCT07285044
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
    II 期 · 干预性 · 2025/12/18Mayo Clinic
    美国
  • 招募中NCT06887348
    A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
    观察性 · 2025/12/12Replimune, Inc.
    澳大利亚、美国
  • 招募中NCT06947928
    Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
    II 期、III 期 · 干预性 · 2025/12/11TuHURA Biosciences, Inc.
    美国
  • 招募中NCT04119024
    Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
    I 期 · 干预性 · 2025/10/07Anusha Kalbasi
    美国
  • 招募中NCT06940440
    IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
    I 期 · 干预性 · 2025/10TuHURA Biosciences, Inc.
    美国
  • 招募中NCT06814496
    Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
    I 期、II 期 · 干预性 · 2025/09/08University of Arizona
    美国

外部标识与链接

OrphanetMONDO:0019210GARD:9266ICD-10 C44.3、C44.6、C44.7ICD-11 2C34ClinicalTrials.gov 检索

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)